On January 20, 2026, Richard A. Heyman, a director at Enliven Therapeutics Inc (NASDAQ:ELVN), sold a total of 1,230 shares of the company’s common stock, generating proceeds of approximately $32,901. This transaction was carried out in two tranches.
The initial sale involved 512 shares at an average price of $26.4592 per share, with individual trade prices ranging from $25.7133 up to $26.7111. Following this, Heyman executed a second transaction selling 718 shares at an average price of $26.956 each, with the transaction prices spanning from $26.725 to $27.3454.
Post these sales, Heyman retains direct ownership of 123,673 shares in Enliven Therapeutics. Additionally, he holds indirect interests through holdings of 23,877 shares via the Heyman Daigle Trust and 25,545 shares held by RAHD Capital LLC. The stock offloading was conducted under a pre-established Rule 10b5-1 trading plan, which was initiated on November 15, 2024.
In parallel with this insider transaction, Enliven Therapeutics disclosed positive initial results from its Phase 1b clinical trial evaluating ELVN-001, its investigational therapy targeting chronic myeloid leukemia (CML). The trial data indicated a cumulative major molecular response (MMR) rate reaching 69% within 24 weeks. Moreover, 53% of patients achieved this MMR milestone within the same timeframe. The study also highlighted that 35% of participants in randomized cohorts attained a deep molecular response.
With an eye towards advancing its clinical pipeline, Enliven plans to initiate a Phase 3 trial later in the year. The company’s leadership has evolved with the addition of Scott Garland to the Board of Directors, bringing over three decades of expertise in commercial leadership. Additionally, Rick Fair has been appointed as the new Chief Executive Officer, replacing co-founder Sam Kintz as part of the company’s strategic development efforts.
These leadership updates coincide with Enliven’s ongoing preparations for its upcoming trials and broader strategy execution. However, the competitive landscape remains dynamic, with emerging data from peers showcased at the American Society of Hematology (ASH) Annual Meeting potentially impacting market positioning.
This detailed overview integrates all available information as verified and reviewed per standard editorial protocols.